

You May Also Like

Hypoglycemia in Diabetes: Does Insulin Type Matter?

Opinion | July 4, 2017 |

Effect of Insulin Degludec vs Insulin Glargine U100 on Hypoglycemia in Patients With Type 1 Diabetes: The SWITCH 1 Randomized Clinical Trial

Research | July 4, 2017 |



This Issue

Views **762**

Citations **0**



145



Original Investigation

More

July 4, 2017

Effect of Insulin Degludec vs Insulin Glargine U100 on Hypoglycemia in Patients With Type 2 Diabetes

The SWITCH 2 Randomized Clinical Trial

Carol Wysham, MD¹; Anuj Bhargava, MD²; Louis Chaykin, MD³; [et al](#)

[□ Author Affiliations](#)

JAMA. 2017;318(1):45-56. doi:10.1001/jama.2017.7117

[□ Editorial
Comment](#)

[□ Related
Articles](#)

Key Points

Question Is the rate of hypoglycemia lower with insulin degludec vs insulin glargine U100 in insulin-treated patients with type 2 diabetes?

Findings In this randomized crossover clinical trial of 721 patients, insulin degludec resulted in a significantly lower rate of overall symptomatic hypoglycemic episodes over a 16-week maintenance period compared with insulin glargine U100 (186 vs 265 episodes per 100 patient-years of exposure, respectively).

Meaning Patients with type 2 diabetes treated with insulin degludec compared with insulin glargine U100 had a reduced risk of overall symptomatic hypoglycemia.

Abstract

Importance Hypoglycemia, a serious risk for insulin-treated patients with type 2 diabetes, negatively affects glycemic control.

Objective To test whether treatment with basal insulin degludec is associated with a lower rate of hypoglycemia compared with insulin glargine U100 in patients with type 2 diabetes.

Design, Setting, and Participants Randomized, double-blind, treat-to-target crossover trial including two 32-week treatment periods, each with a 16-week titration period and a 16-week maintenance period. The trial was conducted at 152 US centers between January 2014 and December 2015 in 721 adults with type 2 diabetes and at least 1 hypoglycemia risk factor who were previously treated with basal insulin with or without oral antidiabetic drugs.

Interventions Patients were randomized 1:1 to receive once-daily insulin degludec followed by insulin glargine U100 (n = 361) or to receive insulin glargine U100 followed by insulin degludec (n = 360) and randomized 1:1 to morning or evening dosing within each treatment sequence.

Main Outcomes and Measures The primary end point was the rate of overall symptomatic hypoglycemic episodes (severe or blood glucose confirmed [<56 mg/dL]) during the maintenance period. Secondary end points were the rate of nocturnal symptomatic hypoglycemic episodes (severe or blood glucose confirmed, occurring between 12:01 AM and 5:59 AM) and the proportion of patients with severe hypoglycemia during the maintenance period.

Results Of the 721 patients randomized (mean [SD] age, 61.4 [10.5] years; 53.1% male), 580 (80.4%) completed the trial. During the maintenance period, the rates of overall symptomatic hypoglycemia for insulin degludec vs insulin glargine U100 were 185.6 vs 265.4 episodes per 100 patient-years of exposure (PYE) (rate ratio = 0.70 [95% CI, 0.61-0.80]; $P < .001$; difference, -23.66 episodes/100 PYE [95% CI, -33.98 to -13.33]), and the proportions of patients with hypoglycemic episodes were 22.5% vs 31.6% (difference, -9.1% [95% CI, -13.1% to -5.0%]). The rates of nocturnal symptomatic hypoglycemia with insulin degludec vs insulin glargine U100 were 55.2 vs 93.6 episodes/100 PYE (rate ratio = 0.58 [95% CI, 0.46-0.74]; $P < .001$; difference, -7.41 episodes/100 PYE [95% CI, -11.98 to -2.85]), and the proportions of patients with hypoglycemic episodes were 9.7% vs 14.7% (difference, -5.1% [95% CI, -8.1% to -2.0%]). The proportions of patients experiencing severe hypoglycemia during the maintenance period were 1.6% (95% CI, 0.6%-2.7%) for insulin degludec vs 2.4% (95% CI, 1.1%-3.7%) for insulin glargine U100 (McNemar $P = .35$; risk difference, -0.8% [95% CI, -2.2% to 0.5%]). Statistically significant reductions in overall and nocturnal symptomatic hypoglycemia for insulin degludec vs insulin glargine U100 were also seen for the full treatment period.

Conclusions and Relevance Among patients with type 2 diabetes treated with insulin and with at least 1 hypoglycemia risk factor, 32 weeks' treatment with insulin degludec vs insulin glargine U100 resulted in a reduced rate of overall symptomatic hypoglycemia.

Trial Registration clinicaltrials.gov Identifier: [NCT02030600](https://clinicaltrials.gov/ct2/show/study/NCT02030600)



Editorial

Hypoglycemia in Diabetes

Full Text

Advertisement



OPIOIDS

Explore Articles About
Opioid Use and Addiction

Learn more



Read More About

Clinical Pharmacy and Pharmacology

Endocrinology

Diabetes

<p>Download PDF</p>
<p><input type="checkbox"/> Full Text</p>
<p><input type="checkbox"/> Cite This</p>
<p><input type="checkbox"/> Permissions</p>

You May Also Like

Opinion

Hypoglycemia in Diabetes: Does Insulin Type Matter?

Research

Effect of Insulin Degludec vs Insulin Glargine U100 on Hypoglycemia in Patients With Type 1 Diabetes: The SWITCH 1 Randomized Clinical Trial

News

Thiazide Diuretics Protect Bones as Well as Hearts

Advertisement

PHYSICIAN JOBS

Find Internal Medicine Jobs Now

You May Also Like

The Need to Test Strategies Based on Common Sense

JAMA Internal Medicine | *Opinion* | July 1, 2017 |

Hypoglycemia in Diabetes: Does Insuli

JAMA | *Opinion* | July 4, 2017 |

rtisement

<p><input type="checkbox"/> JAMA®</p>	<p><input type="checkbox"/> The JAMA Network®</p>	<p><input type="checkbox"/> Help</p>
<p>CONTENT</p> <ul style="list-style-type: none"> Home New Online Current Issue 	<p>JOURNALS</p> <ul style="list-style-type: none"> JAMA® JAMA Cardiology JAMA Dermatology JAMA Facial Plastic Surgery JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery 	<ul style="list-style-type: none"> Subscriptions & Renewals Email Subscriptions Update Your Address Contact Us Frequently Asked Questions
<p>JOURNAL INFORMATION</p> <ul style="list-style-type: none"> For Authors Editors & Publishers RSS Contact Us 	<ul style="list-style-type: none"> Archives of Neurology & Psychiatry (1919-1959) 	<p>JAMA CAREER CENTER</p> <ul style="list-style-type: none"> Physician Job Listings
<ul style="list-style-type: none"> <input type="checkbox"/> Learning <input type="checkbox"/> Store <input type="checkbox"/> Apps <input type="checkbox"/> Jobs <input type="checkbox"/> Institutions <input type="checkbox"/> Reprints & Permissions 	<p>SITES</p> <ul style="list-style-type: none"> AMA Manual of Style Art and Images in Psychiatry Breast Cancer Screening Guidelines Colorectal Screening Guidelines Declaration of Helsinki Depression Screening Guidelines Evidence-Based Medicine: An Oral History Genomics and Precision Health 	<div style="display: flex; flex-wrap: wrap;"> <div style="width: 33%;"><input type="checkbox"/></div> <div style="width: 33%;"><input type="checkbox"/></div> <div style="width: 33%;"><input type="checkbox"/></div> <div style="width: 33%;"><input type="checkbox"/></div> <div style="width: 33%;"><input type="checkbox"/></div> <div style="width: 33%;"><input type="checkbox"/></div> <div style="width: 33%;"><input type="checkbox"/></div> <div style="width: 33%;"><input type="checkbox"/></div> </div>
<p style="text-align: right;">Subscribe</p>		<p>Get the latest from JAMA</p> <div style="border: 1px solid #ccc; width: 100px; height: 30px; margin-bottom: 5px;"></div> <p style="background-color: #c00; color: white; padding: 5px; text-align: center; font-weight: bold;">Sign Up</p>



G
O

Health Disparities
Hypertension Guidelines
JAMA Network Audio
Med Men
Medical Education
Opioid Management Guidelines
Peer Review Congress
Sepsis and Septic Shock
Statins and Dyslipidemia
Topics and Collections

FEATURED ARTICLES

ACS Breast Cancer Screening Guideline
CDC Guideline for Prescribing Opioids
Consensus Definitions for Sepsis and Septic Shock
Income and Life Expectancy in the US
JNC 8 Guideline for Management of High Blood Pressure
President Obama on US Health Care Reform
Screening for Colorectal Cancer
Screening for Depression in Adults
Statins for Primary Prevention of Cardiovascular Disease
WMA Declaration of Helsinki, 7th Revision

BLOGS

The JAMA Forum
Topics in Ophthalmology

INFORMATION FOR

Authors
Institutions &
Librarians

Advertisers

Subscription Agents

Employers & Job
Seekers

Media

JAMA NETWORK PRODUCTS

AMA Manual of Style

JAMAevidence®

JN Challenge™

JN Reader™

Peer Review Congress

LEARNING

CME Quizzes

About CME & MOC

MOC Reporting
Preferences



The **JAMA** Network®

© 2017 American Medical Association. All

Rights Reserved.

[Terms of Use](#) | [Privacy Policy](#) | [Accessibility](#)

[Statement](#)

POWERED BY  **SILVERCHAIR**
INFORMATION/SYSTEMS